News

Kristen Hsu, ARC’s Executive Director of Research, shared the latest updates on ATTR (transthyretin amyloidosis) clinical trials and what these developments mean…

AbstractBACKGROUND:Transthyretin amyloid cardiomyopathy (ATTR-CM) causes a restrictive cardiomyopathy resulting in heart failure (HF). Signaling pathways associated…

Treatments that target the transthyretin (TTR) protein, either by stabilizing it or reducing its production, were associated with about a one-third lower risk of…

Chicago, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The global amyloidosis therapeutics market was valued at 2.95 billion in 2024 and is expected to reach US$ 6.37 billion…

Study OverviewBrief SummaryThis study intends to conduct a prospective observation to investigate the prevalence of cardiac amyloidosis (CA) in patients with aortic…

As per DataM intelligence research report "The global transthyretin amyloid cardiomyopathy (ATTR-CM) was valued at US$ 2.92 Billion n 2023. The global transthyretin…

A new study published in Open Heart provided up-to-date data on the epidemiology of amyloid transthyretin (ATTR) amyloidosis in the US. “Our findings…

AbstractAmyloidosis is a group of disorders caused by extracellular deposition of insoluble fibrillar proteins, leading to progressive organ dysfunction. Cardiac…

Bayer, a global leader in radiology and cardiology, has struck a major deal to acquire two investigational molecular imaging agents from clinical-stage…

Prof. Liu Cong from the Shanghai Institute of Organic Chemistry of the Chinese Academy of Sciences, along with collaborators, has revealed the high-resolution…